PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1498787
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1498787
Plasma Fractionation Market size was valued at USD 29,093 million in 2023, expanding at a CAGR of 7.10% from 2024 to 2032.
The Plasma Fractionation Market involves the separation of plasma from donated blood into its various components for therapeutic and medical use. The increasing prevalence of immunological disorders, rising demand for plasma-derived therapies, and advancements in fractionation technologies are driving the market growth. However, restraints such as the high cost of plasma fractionation processes, stringent regulatory requirements, and limited supply of plasma may hinder market growth. Nevertheless, opportunities lie in the expanding applications of plasma-derived products in treating rare and chronic diseases, ongoing research and development efforts, and growing healthcare infrastructure in emerging economies, which are expected to fuel market expansion in the coming years.
Plasma Fractionation Market- Market Dynamics
Rising Prevalence of Chronic Diseases Drives Growth in Plasma Fractionation Market
The rising prevalence of chronic diseases is significantly driving growth in the plasma fractionation market. For instance, according to the World Health Organization, chronic diseases such as cardiovascular diseases, cancer, and diabetes account for approximately 74% of all deaths worldwide. This increasing burden of chronic illnesses has led to a heightened demand for plasma-derived therapies, which are crucial in managing conditions like hemophilia, immune deficiencies, and other coagulation disorders. Governments and health organizations globally are recognizing the importance of plasma fractionation, leading to initiatives that enhance plasma collection and fractionation capabilities. For example, the U.S. Department of Health and Human Services has been actively involved in initiatives to improve plasma donation and fractionation processes to ensure a steady supply of these critical therapies. This surge in demand, coupled with technological advancements, is expected to further propel the growth of the plasma fractionation market.
Plasma Fractionation Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.10% over the forecast period (2024-2032)
Based on product type segmentation, Immunoglobulins were predicted to show maximum market share in the year 2023
Based on Technology segmentation, Chromatography was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Plasma Fractionation Market is segmented on the basis of Product Type, Technology, Application, and Region.
The market is divided into five categories based on product type: Fractionation Systems, Immunoglobulins, Albumin, Coagulation Factors, and Protease Inhibitors. Immunoglobulins hold a higher share compared to fractionation systems, albumin, coagulation factors, and protease inhibitors in the plasma fractionation market. This dominance is driven by the increasing use of immunoglobulins in treating various immune deficiencies, autoimmune disorders, and neurological diseases.
The market is divided into two categories based on Technology: Chromatography, Electrophoresis, and Ultrafiltration. Chromatography holds a higher share compared to electrophoresis and ultrafiltration in the plasma fractionation market. This prominence is due to its efficiency, high resolution, and ability to separate complex mixtures, making it the preferred technology for producing high-purity plasma-derived products.
Plasma Fractionation Market- Geographical Insights
valence of chronic diseases, and significant investment in research and development. Europe follows, with countries like Germany, France, and the UK having robust plasma collection systems and supportive government policies. The Asia Pacific region is experiencing rapid market growth due to increasing healthcare expenditure, rising awareness about plasma-derived therapies, and a growing prevalence of chronic diseases in countries such as China and India. Latin America and the Middle East & Africa regions present emerging opportunities, driven by improving healthcare infrastructure and increasing focus on expanding plasma fractionation capabilities.
Major companies such as CSL Behring, Grifols, Shire (now part of Takeda Pharmaceutical Company), and Octapharma dominate the market, leveraging their extensive product portfolios and strong global distribution networks. These industry leaders invest heavily in research and development to introduce advanced plasma-derived therapies and improve fractionation processes. Additionally, strategic collaborations, mergers, and acquisitions are common, and aimed at expanding product offerings and geographic reach. For example, Grifols' acquisition of Biotest AG has strengthened its market position and broadened its plasma product range. Emerging companies and regional players are also contributing to market dynamics by focusing on niche segments and regional demands, fostering a competitive environment that drives continuous innovation and market expansion.
In April 2023, CSL (Australia) obtained FDA approval for a 50mL/10gm prefilled syringe of Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid), intended for patients with Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
In March 2022, Grifols (Spain) obtained European approvals for XEMBIFY, a 20% subcutaneous immunoglobulin (SCIG), expanding treatment options for patients with various immunodeficiency disorders.
GLOBAL PLASMA FRACTIONATION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Bio Products Laboratory Ltd.
Biotest AG
China Biologic Products Holdings, Inc.
CSL Behring LLC
Grifols, S.A.
Kedrion S.p.A.
LFB S.A.
Octapharma AG
Sanquin
Shire (Takeda Pharmaceutical Company Limited)
Others